Ionis has won an FDA label expansion for Tryngolza (treatment for severe hypertriglyceridemia), expanding the drug’s commercial address beyond prior use cases. The approval also ties the therapy to risk reduction connected with pancreatitis in patients with dangerously high triglyceride levels. The expanded indication is expected to increase Tryngolza’s patient reach in a market where lipid-lowering options are increasingly differentiated by durability, mechanism, and ability to reduce pancreatitis risk. For antisense developers, it reinforces the regulator’s willingness to broaden label scope when the clinical data support benefit tied to a specific high-risk population. (Article references: Ionis FDA label expansion coverage.)